Phyllis Morgan on Health Disparities in Patients At Risk for Developing Colorectal Cancer
Phyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.
To kick off Colorectal Cancer Awareness month, CancerNetwork® was joined by Phyllis Morgan, PhD, who is an academic coordinator for the Master of Science in Nursing degree program at Walden University, to discuss the most prevalent treatment disparities related to racial and ethnic minorities who are at risk for developing colorectal cancer (CRC).
“We know that African Americans tend to die more from colorectal cancer than other racial groups, with a mortality rate that’s about 40% higher than in other groups,” Morgan said. “Also, they are diagnosed with colorectal cancer more [frequently] than other ethnic groups.”
Morgan went on to say there are different reasons for that, including factors related to detection and screening. To mitigate these challenges, she said education about risk factors, signs and symptoms of the disease, detection methods, as well as treatment modalities are all key areas of need.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
